An Australian pharmaceutical company with a major presence in central Indiana has hit a major milestone. Telix Pharmaceuticals Inc., which has its U.S. headquarters in Fishers, has received approval from the U.S. Food and Drug Administration for its lead prostate cancer imaging product.
Telix says Illuccix is a kit for the preparation of what is known as PSMA-PET imaging, which is used to find lesions in certain prostate cancer patients. The company says the product provides better flexibility and access to the imaging process.
This heralds a new era of patient and physician access to gallium-based PSMA-PET imaging and marks an important new stage for Telix as we bring our first commercial product to market in the United States,” said Dr. Christian Behrenbruch, chief executive officer of Telix. “Improved imaging can provide physicians with the insights to determine the most appropriate treatment pathway and give patients in the U.S. access to a specific and sensitive imaging tool for the detection of prostate cancer throughout the body.”
Telix says it will be able to provide Illuccix to more than 85% of eligible PET imaging sites throughout the United States through its distribution network of more than 140 nuclear pharmacies.
In July, Telix announced plans to add 20 executive-level and administrative jobs in Fishers.